(LON:MEDG, LON:MEDU, NYSE:MDGN), one of the best performing stocks of
last year, has kicked off the clinical trial of its INFRADURE Biopump
treatment of hepatitis C.
The first patient has signed up for the phase I/II clinical trial, which will be the first trial for INFRADURE.
INFRADURE is a skin tissue implant which provides a continuous delivery of interferon-alpha (INFa).